Astellas Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Astellas Pharma has a total shareholder equity of ¥1,503.3B and total debt of ¥873.1B, which brings its debt-to-equity ratio to 58.1%. Its total assets and total liabilities are ¥3,368.7B and ¥1,865.4B respectively. Astellas Pharma's EBIT is ¥116.8B making its interest coverage ratio -45.1. It has cash and short-term investments of ¥285.4B.
Key information
58.1%
Debt to equity ratio
JP¥873.13b
Debt
| Interest coverage ratio | -45.1x |
| Cash | JP¥285.44b |
| Equity | JP¥1.50t |
| Total liabilities | JP¥1.87t |
| Total assets | JP¥3.37t |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4503 N's short term assets (¥1,050.1B) do not cover its short term liabilities (¥1,153.7B).
Long Term Liabilities: 4503 N's short term assets (¥1,050.1B) exceed its long term liabilities (¥711.7B).
Debt to Equity History and Analysis
Debt Level: 4503 N's net debt to equity ratio (39.1%) is considered satisfactory.
Reducing Debt: 4503 N's debt to equity ratio has increased from 0.1% to 58.1% over the past 5 years.
Debt Coverage: 4503 N's debt is well covered by operating cash flow (24.7%).
Interest Coverage: 4503 N earns more interest than it pays, so coverage of interest payments is not a concern.